By Deena Beasley April 30 (Reuters) - Amgen on Thursday reported first-quarter product sales rose 4%, helped by demand for ...
Biotech company Amgen (NASDAQ:AMGN) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 5.8 ...
Learn more THOUSAND OAKS, Calif., April 30, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2026. "Our first quarter results demonstrate the ...
The biotechnology company reported a profit of $1.82 billion, driven by a 4% rise in product sales.
Amgen Inc. reported better-than-expected first-quarter results but only minimally raised its profit guidance, a conservative move as the biotechnology company prepares for increasing competition over ...
Investor's Business Daily on MSN
Amgen's numbers are out: It gets to keep its cholesterol crown — for now
Amgen widely beat the Street's first-quarter expectations late Thursday, slightly ticking its 2026 guidance higher.
The Dow Jones Industrial Average is rallying Thursday morning with shares of Caterpillar and Amgen delivering strong returns for the index. Shares of Caterpillar Caterpillar Inc.
Apple — Shares were up 2%. For the fiscal second quarter , Apple's earnings came in at $2.01 per share, while revenue landed ...
The U.S. Food and Drug Administration's Center for Drug Evaluation and Research on Monday proposed withdrawing approval of ...
Amgen (AMGN) and AstraZeneca (AZN) begin real-time clinical trials as the FDA plans to launch a pilot to accelerate drug ...
Amgen is projected to report a nearly 3% fall in its Q1 earnings on April 30, after the closing bell. The consensus EPS Estimate is $4.77, while the revenue estimate is $8.57B, tr ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results